The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
Abstract
BACKGROUND Dupilumab, the first biological drug to be approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults has shown good efficacy and safety in clinical trials. OBJECTIVE To evaluate real-world data on the efficacy and safety of dupilumab in AD. METHODS Pubmed and Embase were searched for observational studies with data on efficacy, drug survival and safety of dupilumab for the treatment of AD. Primary outcomes were mean percentage change in Eczema Area and Severity Index (EASI), and proportion of AD patients achieving 50%, 75% and 90% improvement in EASI (EASI-50, 75 and 90) following dupilumab therapy. RESULTS 22 unique studies encompassing 3,303 AD patients were included. After 16 weeks of dupilumab therapy, the pooled proportion of patients achieving EASI-50, EASI-75 and EASI-90 was 85.1%, 59.8% and 26.8%, and the weighted mean reduction in EASI was 69.6%. Conjunctivitis was the most common adverse event, reported in a pooled proportion of 26.1%. LIMITATIONS Limited data in terms of size and follow-up time was available. CONCLUSION Real-world data show that dupilumab is a successful and well-tolerated therapy for AD, but ocular adverse events commonly occur. Registries are needed to monitor for adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationDupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Epidemiology of atopic dermatitis in adults: Results from an international survey
Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E. L., Margolis, D. J., de Bruin‐Weller, M., & Eckert, L. (2018) · Allergy · doi:10.1111/all.13401 · Cited by 876
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Cited by
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
The evolving atopic dermatitis management landscape
Sahni, V. N., Balogh, E. A., Strowd, L. C., & Feldman, S. R. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999412 · Cited by 20
Shi, V. Y., Chamberlain, W., Siegfried, E., Kraff-Cooper, C., Beckman, K., Lio, P., Paller, A. S., & Simpson, E. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.01.043 · Cited by 18
Review of Tralokinumab in the Treatment of Atopic Dermatitis
Singh, R., Taylor, A., Shah, M. A., Strowd, L. C., & Feldman, S. R. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221105686 · Cited by 10
Metadata
- Authors
- Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 84
- Issue
- 1
- Pages
- 139-147
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3063829097
- Cited by
- 288
- References
- 40
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/j.jaad.2020.08.051
- The paper
- Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P. (2021). Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.08.051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.